Free Trial
NYSE:ENOV

Enovis (ENOV) Stock Price, News & Analysis

Enovis logo
$34.67 -0.43 (-1.23%)
Closing price 04/28/2025 03:59 PM Eastern
Extended Trading
$34.66 -0.02 (-0.04%)
As of 04/28/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enovis Stock (NYSE:ENOV)

Key Stats

Today's Range
$34.34
$35.54
50-Day Range
$30.60
$44.55
52-Week Range
$29.32
$56.43
Volume
1.10 million shs
Average Volume
753,303 shs
Market Capitalization
$1.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.50
Consensus Rating
Moderate Buy

Company Overview

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Enovis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

ENOV MarketRank™: 

Enovis scored higher than 55% of companies evaluated by MarketBeat, and ranked 425th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Enovis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enovis' stock forecast and price target.
  • Earnings Growth

    Earnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enovis is -15.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enovis is -15.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enovis has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enovis' valuation and earnings.
  • Percentage of Shares Shorted

    10.50% of the float of Enovis has been sold short.
  • Short Interest Ratio / Days to Cover

    Enovis has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Enovis has recently increased by 3.70%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Enovis does not currently pay a dividend.

  • Dividend Growth

    Enovis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.50% of the float of Enovis has been sold short.
  • Short Interest Ratio / Days to Cover

    Enovis has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Enovis has recently increased by 3.70%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Enovis has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Enovis this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for ENOV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enovis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Enovis is held by insiders.

  • Percentage Held by Institutions

    98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enovis' insider trading history.
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Enovis appoints Damien McDonald as CEO
Enovis backs Q1 revenue view $555M-$563M, consensus $558.79M
See More Headlines

ENOV Stock Analysis - Frequently Asked Questions

Enovis' stock was trading at $43.88 at the start of the year. Since then, ENOV stock has decreased by 21.0% and is now trading at $34.67.
View the best growth stocks for 2025 here
.

Enovis Co. (NYSE:ENOV) posted its earnings results on Wednesday, February, 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a positive trailing twelve-month return on equity of 4.39% and a negative net margin of 5.95%.
Read the conference call transcript
.

Top institutional shareholders of Enovis include DAVENPORT & Co LLC (5.38%), Artemis Investment Management LLP (1.22%), Principal Financial Group Inc. (0.49%) and Allspring Global Investments Holdings LLC (0.49%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner.
View institutional ownership trends
.

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/26/2025
Today
4/28/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Current Symbol
NYSE:ENOV
Employees
6,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.50
High Stock Price Target
$64.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+68.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
12.43
P/E Growth
N/A
Net Income
$-33,260,000.00
Pretax Margin
-7.07%

Debt

Sales & Book Value

Annual Sales
$2.11 billion
Cash Flow
$5.05 per share
Price / Cash Flow
6.86
Book Value
$62.66 per share
Price / Book
0.55

Miscellaneous

Free Float
55,494,000
Market Cap
$1.98 billion
Optionable
Optionable
Beta
1.86
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSE:ENOV) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners